Dr. Domenica Lorusso discussed the survival analysis of the PAOLA1 trial – International Journal of Gynecological Cancer

International Journal of Gynecological Cancer shared on LinkedIn:

“New episode of Weekly Podcast
Dr. Domenica Lorusso discussed the survival analysis of the PAOLA1 trial.

Highlights

• Bev+Olaparib has reported increased PFS and OS in advanced stage III-IV, newly diagnosed, high grade serous and endometrioid HRD+ ovarian cancer in the maintenance setting.
• Exploratory analysis suggest that the advantage is particularly high in low-risk patients (stage III without residual tumor at primary surgery), where a 5-y OS more than 90% has been reported suggesting some of these patients may be cured.
• In the HRp population the combination of Olaparib+Bev did non increase PFS and OS in comparison to Bev alone.
• The toxicity profile of the combination is in line with what expected with the single drugs.”

Video attached to the post.
Source: International Journal of Gynecological Cancer/LinkedIn